Warning Letter Record: Peptide Partners LLC (2026-08-24) — Unapproved New Drugs/Misbranded
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs/Misbranded
TL;DR
In short: **FDA Warning Letter to Peptide Partners LLC (CDER, August 24, 2026)** The FDA's Center for Drug Evaluation and Research identified seven unapproved new drugs marketed by Peptide Partners LLC via its website (peptide.partners): GLP-1 S (Semaglutide), GLP-2 T (Tirzepatide), GLP-3 Reta (Retatrutide), SS-31 (Elamipretide), Tesa Peptide (Tesamorelin), PT-141 (Bremelanotide), and Reconstitution Solution (BAC). The products' website labeling makes disease treatment and health effect claims—including bone health, metabolism improvement, blood sugar control, weight loss, kidney protection, and cancer treatment potential—establishing them as drugs under the Federal Food, Drug, and Cosmetic Act without required FDA approval. The FDA stated these injectable products pose particular public health risk due to direct delivery into the body, bypassing natural defenses against toxins and microorganisms.
Argus analysis
# FDA Warning Letter Analysis: Peptide Partners LLC
**Company and Violations**
Peptide Partners LLC, operating from Sarasota, Florida, received a warning letter dated August 24, 2026, from FDA's Center for Drug Evaluation and Research (CDER). The agency identified seven peptide products sold through the company's website as unapproved new drugs: semaglutide, tirzepatide, retatrutide, elamipretide, tesamorelin, bremelanotide, and a reconstitution solution (BAC). FDA's review in July 2026 found that product labeling made disease-treatment claims—such as potential benefits for bone health, metabolic improvement, kidney protection, and cancer treatment—establishing these compounds as drugs rather than research chemicals. Injectable products pose heightened public health concern because they bypass the body's natural defenses against contamination and toxins.
**Regulatory Citations**
The violations cite sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(a) and 331(d)), along with section 201(g)(1) defining drugs by intended use. Products making claims about disease diagnosis, treatment, mitigation, or prevention—or affecting body structure or function—meet the definition of a drug under 21 CFR 201.128. FDA determined these peptides are "new drugs" under section 201(p) because they lack recognized safe and effective status (GRASE) for their labeled uses. Marketing materials disclaiming "research use only" status do not override actual intended-use evidence demonstrated through website content.
**Response Timeline and Industry Watch Points**
Peptide Partners has 15 business days from letter receipt to submit a written response to FDAAdvisory@fda.hhs.gov, detailing corrective steps and preventative measures. Compliance officers in the peptide and specialty pharmaceutical sector should monitor whether the company ceases sales, removes disease claims, or pursues other remedies. Failure to respond adequately within this window could trigger seizure or injunction actions. The letter is posted publicly on FDA's website, making future regulatory scrutiny more likely.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Peptide Partners LLC MARCS-CMS 735063 — August 24, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: Recipient Name Zachary David Hoff Peptide Partners LLC 8350 Bee Ridge, #379 Sarasota , FL 34241-9607 United States support@peptide.partners (b)(6), (b)(7)(C) Issuing Office: Center for Drug Evaluation and Research (CDER) United States August 24, 2026 Pirsek Technologies 6776 Timberland Lane Sarasota, FL 34241-9760 WARNING LETTER Reference Number: 735063 To Zachary David Hoff: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions. FDA Review Violations were identified and documented during a review of your website https://peptide.partners/ in July 2026. Based on our review,“GLP-1 S (Semaglutide),” “GLP-2 T (Tirzepatide),” “GLP-3 Reta (Retatrutide),” “SS-31 (Elamipretide),” “Tesa Peptide (Tesamorelin),” “PT-141 (Bremelanotide),” and “Reconstitution Solution (BAC)” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations. Unapproved New Drug Violations Based on a review of your website, “GLP-1 S (Semaglutide),” “GLP-2 T (Tirzepatide),” “GLP-3 Reta (Retatrutide),” “SS-31 (Elamipretide),” “Tesa Peptide (Tesamorelin),” “PT-141 (Breme…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Peptide Partners LLC had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Peptide Partners LLC as of 2026-09-01. Argus ingests new FDA enforcement records daily.
- What FDA violations was Peptide Partners LLC cited for?
- The FDA Warning Letter to Peptide Partners LLC (issuing office: Center for Drug Evaluation and Research (CDER)) cites: Unapproved New Drugs/Misbranded. Classification: Unapproved drug.
- When did FDA issue the warning letter to Peptide Partners LLC?
- FDA issued the letter (MARCS-CMS 735063) on 2026-08-24 and posted it publicly on fda.gov on 2026-09-01.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Warning Letter Record: Peptide Partners LLC (2026-08-24) — Unapproved New Drugs/Misbranded. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-peptide-partners-llc-2026-08-24-unapproved-drug
"Warning Letter Record: Peptide Partners LLC (2026-08-24) — Unapproved New Drugs/Misbranded." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-peptide-partners-llc-2026-08-24-unapproved-drug.
Argus HQ Research. "Warning Letter Record: Peptide Partners LLC (2026-08-24) — Unapproved New Drugs/Misbranded." Digital Empire Holdings LLC. Accessed September 2, 2026. https://argushq.ai/fda/warning-letter/fda-wl-peptide-partners-llc-2026-08-24-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_peptide_partners_llc_2026_08_24_unapproved_drug_2026,
title = {Warning Letter Record: Peptide Partners LLC (2026-08-24) — Unapproved New Drugs/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-peptide-partners-llc-2026-08-24-unapproved-drug},
note = {Accessed: September 2, 2026}
}